Concord Bio attracts attention

Concord Biotech is trading marginally higher today morning The stock was up 0.53% at Rs. 1,333.85 on the NSE, tracking a regulatory-led uptick even as investors remain mindful of the company’s softer Q4FY26 print.

Trigger

• The company said it has received US FDA approval for its abbreviated new drug application (ANDA) for Tofacitinib tablets (5 mg and 10 mg).
• Management has cited the combined US market opportunity at USD 500 million for both strengths.
• This follows another recent US FDA approval (Mycophenolate Mofetil), indicating continued progress on the US pipeline.

The market typically assigns a premium to US FDA approvals because they de-risk the regulatory leg of a product and expand the addressable export pool. In Concord’s case, the tofacitinib ANDA adds another large-ticket molecule to its US opportunity set, which can support medium-term growth visibility (subject to launch timing, competition intensity, and pricing dynamics).

That said, the reaction is measured rather than sharp, likely because the street is balancing the positive regulatory update against recent financial performance. Concord reported a weaker Q4FY26, with net profit down 36.8% YoY to Rs. 88.8 crore and revenue from operations down 24.1% YoY to Rs. 326.1 crore.